What to Expect From These Drug/Biotech Players This Earnings Season?Zacks Investment Research • 02/16/26
Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 02/12/26
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASHPRNewsWire • 02/11/26
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA ProgramsGlobeNewsWire • 02/11/26
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026GlobeNewsWire • 02/02/26
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/21/26
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 InhibitorGlobeNewsWire • 01/09/26
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/15/25
Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/04/25
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/20/25
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor ConferencesGlobeNewsWire • 11/17/25
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH CirrhosisGlobeNewsWire • 11/10/25
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock UpZacks Investment Research • 11/05/25